4.6 Article

Stereotactic radio surgery for Spetzler-Martin Grade III arteriovenous malformations

期刊

JOURNAL OF NEUROSURGERY
卷 120, 期 4, 页码 973-981

出版社

AMER ASSOC NEUROLOGICAL SURGEONS
DOI: 10.3171/2013.12.JNS131600

关键词

arteriovenous malformation; Gamma Knife; hemorrhage; stereotactic radiosurgery; Spetzler-Martin grade; vascular disorders

向作者/读者索取更多资源

Object. The purpose of this study was to define the outcomes and risks of stereotactic radiosurgery (SRS) for Spetzler-Martin (SM) Grade III arteriovenous malformations (AVMs). Methods. Between 1987 and 2009, SRS was performed in 474 patients with SM Grade III AVMs. The AVMs were categorized by scoring the size (S), drainage (D), and location (L): Illa was a small AVM (S1D1L1, N = 282); Mb was a medium/deep AVM (S2D1LO, N = 44); and IIIc was a medium/eloquent AVM (S2DOL1, N = 148). The median target volume was 3.8 ml (range 0.1-26.3 ml) and the margin dose was 20 Gy (range 13-25 Gy). Eighty-one patients (17%) underwent prior embolization, and 58 (12%) underwent prior resection. Results. At a mean follow-up of 89 months, the total obliteration rates documented by angiography or MRI for all SM Grade III AVMs increased from 48% at 3 years to 69% at 4 years, 72% at 5 years, and 77% at 10 years. The SM Grade Ma AVMs were more likely to obliterate than other subgroups. The cumulative rate of hemorrhage was 2.3% at 1 year, 4.4% at 2 years, 5.5% at 3 years, 6.4% at 5 years, and 9% at 10 years. The SM Grade Illb AVMs had a significantly higher cumulative rate of hemorrhage. Symptomatic adverse radiation effects were detected in 6%. Conclusions. Treatment with SRS was an effective and relatively safe management option for SM Grade III AVMs. Although patients with residual AVMs remained at risk for hemorrhage during the latency interval, the cumulative 10-year 9% hemorrhage risk in this series may represent a significant reduction compared with the expected natural history.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据